• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Sustained Anlotinib Regimens Stabilize Advanced Soft Tissue Sarcoma Beyond Initial Progression

by
November 18, 2026
in Health
Reading Time: 2 mins read
0
Sustained Anlotinib Regimens Stabilize Advanced Soft Tissue Sarcoma Beyond Initial Progression

Sustained Anlotinib Regimens Stabilize Advanced Soft Tissue Sarcoma Beyond Initial Progression

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Continuing anlotinib-based combination therapy following disease progression demonstrated meaningful disease stabilization in patients with advanced soft tissue sarcoma, according to a multicenter real-world study conducted across specialized Chinese medical centers. The retrospective investigation revealed that sustaining this multitargeted approach provided measurable disease control even after patients experienced prior progression on anlotinib.

Multitarget antiangiogenic tyrosine kinase inhibitors play a pivotal role in the clinical management of soft tissue sarcoma, but acquired therapeutic resistance remains a common hurdle during prolonged care. When progression arises, discontinuing antiangiogenic therapy can potentially trigger rapid tumor rebound, yet clinical evidence examining the continuation of targeted antiangiogenic interventions beyond progressive disease has remained notably limited.

To investigate the clinical outcomes of this management strategy, researchers initiated a retrospective review of medical records gathered from four representative Chinese sarcoma centers. The evaluation systematically gathered data on individuals with advanced soft tissue sarcoma who received sustained anlotinib-based combination regimens after developing documented progression on prior anlotinib therapy, establishing progression-free survival as the primary study endpoint.

The multicenter investigation ultimately included 217 qualifying patients treated between February 15, 2020, and March 31, 2023. At baseline, the participants had a median age of 61 years, with ages extending across a wide range from 26 to 88 years, and 131 individuals, representing 60.4 percent of the overall cohort, were male.

Following a median observation period of 7.4 months, researchers determined that the cohort achieved a median progression-free survival of 4.2 months, accompanied by a 95 percent confidence interval of 3.7 to 4.5 months. Furthermore, the analysis demonstrated that 21.9 percent of the evaluated patients maintained progression-free survival at six months.

Secondary efficacy evaluations revealed no objective responses across the cohort, but 158 patients successfully attained stable disease, culminating in an overall disease control rate of 72.8 percent. The median overall survival had not yet been reached at the conclusion of follow-up, while the 6-month overall survival rate stood at 91.4 percent.

Safety evaluations demonstrated that the prolonged combination treatment strategy exhibited an adverse event profile broadly consistent with earlier published reports regarding anlotinib, with no unexpected toxicities detected. The most frequent treatment-related adverse events documented during therapy were hypertension, occurring in 20.7 percent of participants, and hand-foot syndrome, recorded in 14.7 percent of treated individuals.

The study authors concluded that sustained anlotinib-based combination therapy beyond disease progression demonstrated promising clinical activity alongside an acceptable safety profile in advanced soft tissue sarcoma. Because these clinical findings derive from retrospective multicenter observations, the researchers noted that further validation in future clinical investigations will be necessary to confirm the outcomes.

Subject of Research: Sustained anlotinib combination therapy beyond progression in advanced soft tissue sarcoma

Article Title: Sustained Anlotinib-Based Combination Therapy Beyond Progression in Advanced Soft Tissue Sarcoma: A Large Multicenter Real-World Study

Article References: Yuan, Y., Ye, T., Fan, L., Sun, X., Wang, J., Luo, Z., & Chen, J. (2026). Sustained Anlotinib-Based Combination Therapy Beyond Progression in Advanced Soft Tissue Sarcoma: A Large Multicenter Real-World Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03856-1

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03856-1

Keywords: anlotinib, soft tissue sarcoma, tyrosine kinase inhibitors, antiangiogenic therapy, disease progression, progression-free survival, overall survival, disease control rate, stable disease, hypertension, hand-foot syndrome, real-world study, retrospective study, multicenter study, tumor rebound, combination therapy

News Source: Ophelia Keating. (November 18, 2026). Sustained Anlotinib Regimens Stabilize Advanced Soft Tissue Sarcoma Beyond Initial Progression. Scienmag.

Tags: anlotinibantiangiogenic therapycombination therapydisease control ratedisease progressionhand-foot syndromehypertensionMulticenter Studyoverall survivalprogression-free survivalReal-world studyRetrospective studysoft tissue sarcomastable diseasetumor reboundtyrosine kinase inhibitors
Share12Tweet7Share2ShareShareShare1

Related Posts

Template-Guided Patient-Specific Implants Reduce Chronic Temporomandibular Joint Dislocation Symptoms

Template-Guided Patient-Specific Implants Reduce Chronic Temporomandibular Joint Dislocation Symptoms

November 18, 2026
Maternal PTSD Drives Bidirectional Cycle of Adverse Pregnancy Outcomes for Black Women

Maternal PTSD Drives Bidirectional Cycle of Adverse Pregnancy Outcomes for Black Women

November 18, 2026

Genetic Study Links Air Pollution and Lung Impairment to Alzheimer’s Disease Risk

November 18, 2026

Platelet-to-Lymphocyte Ratio Shows Moderate Accuracy for Detecting Periprosthetic Joint Infections

November 18, 2026

POPULAR NEWS

  • Electrical Nerve Stimulation Reduces Acute Postoperative Pain Following Knee Replacement

    Electrical Nerve Stimulation Reduces Acute Postoperative Pain Following Knee Replacement

    29 shares
    Share 12 Tweet 7
  • Thermodynamic Kinetic Modeling Unifies Ammonia Desorption Across Titanium Silicalite-1 Zeolites

    29 shares
    Share 12 Tweet 7
  • Elevated Waist-to-Height Ratio and HbA1c Linked to Higher Cardiovascular Disease Risk

    29 shares
    Share 12 Tweet 7
  • Silver-Functionalized Chitosan Nanoparticles Enhance Platelet-Rich Plasma for Canine Wound Healing

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Template-Guided Patient-Specific Implants Reduce Chronic Temporomandibular Joint Dislocation Symptoms

Maternal PTSD Drives Bidirectional Cycle of Adverse Pregnancy Outcomes for Black Women

Genetic Study Links Air Pollution and Lung Impairment to Alzheimer’s Disease Risk

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.